Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042149 | 1.00 | KDM4E (0.46) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL7046540 | 1.00 | KDM4E (0.46) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL4024374 | 1.00 | KDM4E (0.46) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL7040650 | 1.00 | KDM4E (0.46) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL7044736 | 1.00 | KDM4E (0.46) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL7045031 | 1.00 | KDM4E (0.46) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL6024558 | 1.00 | KDM4E (0.46) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL9334470 | 0.95 | KDM4E (0.52) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL12112374 | 0.95 | KDM4E (0.52) | KDM4ELMNAL3MBTL1TDP1ADH1B | |
| SCHEMBL11343452 | 0.86 | ADH1B (0.44) | KDM4ELMNAL3MBTL1TDP1ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040185539-A1 | Process for the preparation of 2-hydroxymethyl-pyrolidine 3, 4-diols | LONZA AG (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1379676-A2 | PROCESS FOR THE PREPARATION OF 2-HYDROXYMETHYL-PYROLIDINE-3,4-DIOLS | LONZA AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002074737-A2 | PROCESS FOR THE PREPARATION OF 2-HYDROXYMETHYL-PYROLIDINE-3,4-DIOLS | LONZA AG (CH) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185539-A1 | Process for the preparation of 2-hydroxymethyl-pyrolidine 3, 4-diols | HPD, DHPS, DPYD | KDM4E 652/4885LMNA 985/4885L3MBTL1 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.